Virbac: one of the SBF120's top performers in 2023
For the record, the stock was boosted by an increase in its targets for 2023, with organic sales growth expected to be around 4% and an adjusted EBIT margin of around 15% at constant exchange rates.
With regard to 2024, the veterinary drugs manufacturer said it was currently forecasting organic sales growth of between 4% and 6%, and an adjusted EBIT margin of around 15% at constant exchange rates.
The 2024 guidance leaves room for improvement, during 2024, including with the non-recurrence of the impact of the 2023 cyber-attack", estimated Oddo BHF, maintaining its "outperform" opinion with a price target raised from 290 to 385 euros.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction